MXMGX
Price
$38.81
Change
+$0.32 (+0.83%)
Updated
Sep 20 closing price
RPTIX
Price
$109.40
Change
-$0.77 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

MXMGX vs RPTIX

Header iconMXMGX vs RPTIX Comparison
Open Charts MXMGX vs RPTIXBanner chart's image
Empower T. Rowe Price Mid Cp Gr I
Price$38.81
Change+$0.32 (+0.83%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth I
Price$109.40
Change-$0.77 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
MXMGX vs RPTIX Comparison Chart
Loading...
VS
MXMGX vs. RPTIX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MXMGX is a StrongBuy and RPTIX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RPTIX has more cash in the bank: 31.4B vs. MXMGX (1.83B). RPTIX pays higher dividends than MXMGX: RPTIX (0.18) vs MXMGX (0.00). MXMGX was incepted earlier than RPTIX: MXMGX (27 years) vs RPTIX (9 years). MXMGX is a more actively managed with annual turnover of: 34.00 vs. RPTIX (21.70). MXMGX has a lower initial minimum investment than RPTIX: MXMGX (0) vs RPTIX (500000). MXMGX annual gain was more profitable for investors over the last year : 19.40 vs. RPTIX (14.81). MXMGX return over 5 years is better than : 31.00 vs. RPTIX (15.09).
MXMGXRPTIXMXMGX / RPTIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence27 years9 years-
Gain YTD9.2239.127101%
Front LoadN/AN/A-
Min. Initial Investment0500000-
Min. Initial Investment IRAN/AN/A-
Net Assets1.83B31.4B6%
Annual Yield % from dividends0.000.18-
Returns for 1 year19.4014.81131%
Returns for 3 years-4.85-13.5736%
Returns for 5 years31.0015.09205%
Returns for 10 years73.33N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CLH246.88-0.54
-0.22%
Clean Harbors
TOI0.29N/A
-0.58%
Oncology Institute (The)
CINT6.59-0.04
-0.60%
CI&T
CSTM16.22-0.54
-3.22%
Constellium SE
KTTA4.43-0.37
-7.71%
Pasithea Therapeutics Corp